• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4657932)   Today's Articles (3963)   Subscriber (51245)
For: Behmueller M, Tselis N, Zamboglou N, Zoga E, Baltas D, Rödel C, Chatzikonstantinou G. High-Dose-Rate Brachytherapy as Monotherapy for Low- and Intermediate-Risk Prostate Cancer. Oncological Outcomes After a Median 15-Year Follow-Up. Front Oncol 2021;11:770959. [PMID: 34926278 PMCID: PMC8674679 DOI: 10.3389/fonc.2021.770959] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2021] [Accepted: 11/16/2021] [Indexed: 11/15/2022]  Open
Number Cited by Other Article(s)
1
Salari K, Ye H, Martinez AA, Sebastian E, Limbacher A, Marvin K, Thompson AB, Nandalur SR, Chen PY, Krauss DJ. Mature effectiveness and toxicity outcomes associated with three treatment schedules of high-dose-rate brachytherapy monotherapy for favorable-risk prostate cancer. Brachytherapy 2024:S1538-4721(24)00439-2. [PMID: 39674773 DOI: 10.1016/j.brachy.2024.10.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2024] [Revised: 10/02/2024] [Accepted: 10/16/2024] [Indexed: 12/16/2024]
2
William R, McLaughlin PY, Pharand-Charbonneau M, Wright DS, Haddad A, Gaudet M. Long-term disease-free survival and health-related quality of life results of high-dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer treated in a community cancer center. Brachytherapy 2024:S1538-4721(24)00405-7. [PMID: 39547869 DOI: 10.1016/j.brachy.2024.10.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2024] [Revised: 09/24/2024] [Accepted: 10/09/2024] [Indexed: 11/17/2024]
3
Kawase M, Nakane K, Iinuma K, Kawase K, Taniguchi T, Tomioka M, Tobisawa Y, Koie T. Overall Survival and Cancer-Specific Mortality in Patients with Prostate Cancer Undergoing Definitive Therapies: A Narrative Review. J Clin Med 2024;13:5561. [PMID: 39337047 PMCID: PMC11432447 DOI: 10.3390/jcm13185561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2024] [Revised: 09/11/2024] [Accepted: 09/17/2024] [Indexed: 09/30/2024]  Open
4
Dabic-Stankovic K, Rajkovic K, Stankovic J, Marosevic G, Kolarevic G, Pavicar B. High-dose-rate Brachytherapy Monotherapy in Patients With Localised Prostate Cancer: Dose Modelling and Optimisation Using Computer Algorithms. Clin Oncol (R Coll Radiol) 2024;36:378-389. [PMID: 38584072 DOI: 10.1016/j.clon.2024.03.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2023] [Revised: 02/13/2024] [Accepted: 03/11/2024] [Indexed: 04/09/2024]
5
Nagore G, Moreno-Olmedo E, Suárez-Gironzini V, Aakki L, Li RG, Gómez E, Garcia A, Beltran L, Gomez-Iturriaga A. Long-term outcomes of ultra-hypofractionated 2 fractions single day HDR brachytherapy in localized prostate cancer. Radiother Oncol 2023;186:109807. [PMID: 37437606 DOI: 10.1016/j.radonc.2023.109807] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2023] [Revised: 07/05/2023] [Accepted: 07/05/2023] [Indexed: 07/14/2023]
6
Zeng H, Dai J, Cao D, Wang M, Zhao J, Zeng Y, Xu N, Xie Y, Liu H, Zeng H, Sun G, Shen P. Safety and efficacy associated with single-fraction high-dose-rate brachytherapy in localized prostate cancer: a systematic review and meta-analysis. Strahlenther Onkol 2023;199:525-535. [PMID: 37093230 DOI: 10.1007/s00066-023-02063-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2022] [Accepted: 02/19/2023] [Indexed: 04/25/2023]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA